The following is a statement from Merck in regards to NuvaRing:
Nothing is more important to Merck than the safety of our medicines and vaccines and the people who use them. Merck employees, and our families, use Merck medicines, too. Our deepest sympathies go out to these families.
There is substantial evidence to support the safety and efficacy of NuvaRing, and we stand behind the research that supported the approval of NuvaRing, and our continued work to monitor the safety of the medicine. While there is a very small risk of a blood clot when using NuvaRing or any combined hormonal contraceptive, this risk is much less than the risk of blood clots during pregnancy and the immediate post-partum period. In addition, all combination hormonal contraceptive products in the U.S., including NuvaRing, carry a boxed warning on serious cardiovascular events, especially in women who smoke. Both the FDA-approved patient information and physician package labeling for NuvaRing include this information.
We encourage women to work jointly with their healthcare providers to discuss benefits and risks of any contraception approach before choosing an option that is right for them.
To read the full story, click here.
Copyright 2014 WFSB (Meredith Corporation). All rights reserved.